Alar Pharmaceuticals Inc.

6785.TWO

6785.TWOAlar Pharmaceuticals Inc. TW flag

Taipei Exchange

140.00

TWD

-2.00

(-1.41%)

0.04EPS

3,500.00P/E

9.35BMarket Cap

Aug 06Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

TW0006785009

Return %

Stock

S&P500

-43.20

9.22

204.35

59.29

211.11

93.57

Use logarithmic scale

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	0.1	0.02	- -	0.01	- -	0.01	8.23	0.09	0.08
Basic EPS, GAAP	-3.44	-1.96	-1.94	-2.86	-1.13	-0.35	6.71	0.27	0.06
Free Cash Flow per Basic Share	-24.33	-1.52	-1.98	-2.85	-1.14	-0.6	6.97	-0.59	-0.92
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	1.51	- -
Book Value per Share	3.37	6.04	2.78	3.5	1.94	9.03	15.74	13.3	12.56
Tangible Book Value per Share	1.42	9.06	5.46	11.99	9.37	9.03	15.74	37.64	35.62
Basic Weighted Avg Shares	6	27	35	50	57	57	57	66	70
Sales/Revenue/Turnover	1	- -	- -	1	- -	1	469	6	6
Operating Margin (%)	-3,451	-14,188.6	- -	-28,460.83	- -	-5,815.88	82.15	-1,168.02	-1,537.56
Depreciation Expense	2	2	3	3	3	3	3	4	4
Net Income, GAAP	-21	-54	-68	-143	-64	-20	383	18	4
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	2.17	50.96	72.28
Profit Margin (%)	-3,448.83	-10,753.6	- -	-23,799.5	- -	-2,483.88	81.53	312.36	69.3
Working Capital	1	242	180	587	524	492	828	2,387	2,373
LT Debt	- -	- -	2	1	- -	1	- -	- -	1
Total Equity	20	259	191	599	534	515	897	2,492	2,490
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	51.48	-1.91	-0.96
Return on Capital (%)	- -	- -	- -	- -	- -	- -	54.06	2.04	0.43
Return on Common Equity (%)	- -	-57.89	-51.72	-105.03	-45.09	-6.36	54.21	2.04	0.43

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	-98.76%
Net Income, GAAP	- -	-426.95%	-95.25%
Free Cash Flow	- -	-274.42%	-109.79%
Total Cash Common Dividend	- -	- -	- -
Total Equity	- -	90.2%	177.76%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Dr. Yung-Shun Wen Ph.D.
Full Time Employees: 27
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: No. 32, Keya Road Taichung Taiwan, Province of China
IPO Date: Oct 5, 2020
Website: alarpharm.com
Similar Companies: Adcock Ingram Holdings Limited (AIHLF)
The Hempshire Group, Inc. (HMPSF)
StateHouse Holdings Inc. (STHZ.CN)
WEED, Inc. (BUDZ)
CanSino Biologics Inc. (688185.SS)
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ)
Business: Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	0.1	0.02	- -	0.01	- -	0.01	8.23	0.09	0.08
Basic EPS, GAAP	-3.44	-1.96	-1.94	-2.86	-1.13	-0.35	6.71	0.27	0.06
Free Cash Flow per Basic Share	-24.33	-1.52	-1.98	-2.85	-1.14	-0.6	6.97	-0.59	-0.92
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	1.51	- -
Book Value per Share	3.37	6.04	2.78	3.5	1.94	9.03	15.74	13.3	12.56
Tangible Book Value per Share	1.42	9.06	5.46	11.99	9.37	9.03	15.74	37.64	35.62
Basic Weighted Avg Shares	6	27	35	50	57	57	57	66	70
Sales/Revenue/Turnover	1	- -	- -	1	- -	1	469	6	6
Operating Margin (%)	-3,451	-14,188.6	- -	-28,460.83	- -	-5,815.88	82.15	-1,168.02	-1,537.56
Depreciation Expense	2	2	3	3	3	3	3	4	4
Net Income, GAAP	-21	-54	-68	-143	-64	-20	383	18	4
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	2.17	50.96	72.28
Profit Margin (%)	-3,448.83	-10,753.6	- -	-23,799.5	- -	-2,483.88	81.53	312.36	69.3
Working Capital	1	242	180	587	524	492	828	2,387	2,373
LT Debt	- -	- -	2	1	- -	1	- -	- -	1
Total Equity	20	259	191	599	534	515	897	2,492	2,490
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	51.48	-1.91	-0.96
Return on Capital (%)	- -	- -	- -	- -	- -	- -	54.06	2.04	0.43
Return on Common Equity (%)	- -	-57.89	-51.72	-105.03	-45.09	-6.36	54.21	2.04	0.43

	Sep'24	Dec'24	Mar'25
Total Current Assets	2,436	2,442	2,427
Accounts Receivable, Net	- -	- -	- -
Cash, Cash Equivalents & STI	2,424	2,431	2,412
Inventories	- -	- -	- -
Total Current Liabilities	54	55	54
Payables & Accruals	- -	- -	- -
ST Debt	- -	- -	2
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	-0.29	-0.17	0.03	- -	6.71
2024	0.19	-0.05	-0.22	- -	0.27
2025	-0.03	- -	- -	- -	- -

	Sep'24	Dec'24	Mar'25
ST Debt	- -	- -	2
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	1
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	67	67	67
Market Capitalization	12,309	9,596	9,017

Alar Pharmaceuticals Inc.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year